Profile data is unavailable for this security.
About the company
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
- Revenue in DKK (TTM)17.37bn
- Net income in DKK1.92bn
- Incorporated1950
- Employees5.87k
- LocationH Lundbeck A/SOttiliavej 9VALBY 2500DenmarkDNK
- Phone+45 36301311
- Fax+45 36301940
- Websitehttps://www.lundbeck.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dechra Pharmaceuticals plc | 4.15bn | 237.95m | 26.06bn | 1.73k | 104.38 | 6.26 | 28.02 | 6.28 | 0.2778 | 0.2778 | 4.85 | 4.64 | 0.4904 | 2.05 | 6.25 | 288,214.90 | 2.81 | 3.31 | 3.46 | 3.71 | 57.71 | 56.28 | 5.73 | 6.18 | 0.5463 | 6.41 | 0.3902 | 104.89 | 18.35 | 20.01 | -19.92 | 1.48 | 25.00 | 15.46 |
| Hutchison China MediTech Limited | 1.35bn | -698.97m | 26.27bn | 853.00 | -- | 12.99 | -- | 19.45 | -0.1262 | -0.1262 | 0.2439 | 0.3422 | 0.4109 | 11.23 | 4.75 | 190,331.50 | -20.79 | -8.48 | -27.63 | -11.74 | 21.84 | 29.16 | -50.60 | -16.40 | 2.66 | -- | 0.0956 | -- | -4.31 | 18.60 | -41.73 | -- | 18.09 | -- |
| Richter Gedeon Vegyeszeti Gyar Nyrt | 11.13bn | 1.14bn | 26.34bn | 13.05k | 23.05 | 1.66 | 12.96 | 2.37 | 290.71 | 290.71 | 2,837.40 | 4,024.96 | 0.6127 | 2.27 | 3.66 | 40,507,330.00 | 6.49 | 5.51 | 7.41 | 6.25 | 55.92 | 57.44 | 10.60 | 10.02 | 3.16 | -- | 0.00 | 36.04 | 13.99 | 7.50 | 33.35 | 13.57 | 6.08 | 13.83 |
| Idorsia Ltd | 156.10m | -3.55bn | 26.37bn | 636.00 | -- | 59.90 | -- | 168.91 | -3.87 | -3.87 | 0.1698 | 0.4414 | 0.0199 | -- | 6.30 | -- | -45.33 | -- | -49.95 | -- | -- | -- | -2,280.74 | -- | -- | -887.30 | 0.9214 | -- | -60.71 | -- | -27.75 | -- | -- | -- |
| Evotec SE | 3.44bn | 313.53m | 26.77bn | 3.03k | 84.86 | 7.32 | 60.18 | 7.78 | 0.2797 | 0.2797 | 3.08 | 3.24 | 0.4476 | 39.69 | 6.39 | 152,472.00 | 4.00 | 6.75 | 4.88 | 8.93 | 29.12 | 30.51 | 8.93 | 13.63 | 2.45 | 47.07 | 0.4842 | 0.00 | 18.92 | 37.91 | -54.77 | -- | 43.29 | -- |
| Financiere de Tubize SA | 2.13bn | 2.11bn | 27.92bn | -- | 13.22 | 1.21 | -- | 13.10 | 6.37 | 6.37 | 6.42 | 69.44 | 0.1093 | -- | 4,334.49 | -- | 10.84 | 10.79 | 11.06 | 11.09 | 99.56 | 98.06 | 99.17 | 99.58 | -- | -- | 0.0315 | 9.77 | -0.7546 | 31.94 | -0.5092 | 36.06 | -- | 3.81 |
| MorphoSys AG | 2.30bn | 857.82m | 28.38bn | 516.00 | 32.45 | 5.66 | 31.30 | 12.31 | 3.57 | 3.57 | 9.75 | 20.47 | 0.3272 | 5.35 | 13.40 | 726,360.90 | 12.18 | -12.04 | 13.08 | -13.24 | 99.45 | -- | 37.22 | -74.00 | 12.87 | -- | 0.0668 | -- | -6.13 | 2.32 | -83.39 | -- | -29.11 | -- |
| Hikma Pharmaceuticals Plc | 14.52bn | 3.20bn | 40.31bn | 8.58k | 13.26 | 3.04 | 10.12 | 2.78 | 1.58 | 1.58 | 7.18 | 6.92 | 0.5932 | 1.93 | 3.41 | 203,501.40 | 13.11 | 1.75 | 19.33 | 2.37 | 51.93 | 52.20 | 22.11 | 3.08 | 0.8702 | 15.03 | 0.2434 | 152.65 | 6.12 | 8.15 | 72.34 | 11.82 | 9.53 | 16.51 |
| Swedish Orphan Biovitrum AB (publ) | 11.19bn | 2.57bn | 44.66bn | 1.38k | 17.19 | 3.28 | 11.61 | 3.99 | 12.09 | 12.09 | 52.74 | 63.38 | 0.4089 | 2.25 | 4.85 | 11,701,870.00 | 9.38 | 10.69 | 11.37 | 13.63 | 76.92 | 72.92 | 22.94 | 20.19 | 0.9931 | 15.17 | 0.453 | 0.00 | 55.91 | 40.45 | 36.65 | -- | 121.42 | -- |
| Orion Oyj | 8.12bn | 1.68bn | 46.99bn | 3.32k | 27.93 | 7.46 | 22.40 | 5.79 | 1.60 | 1.60 | 7.76 | 5.99 | 0.892 | 1.88 | 5.52 | 333,782.50 | 18.41 | 20.14 | 26.74 | 25.74 | 60.92 | 60.20 | 20.64 | 20.85 | 2.50 | 156.78 | 0.1587 | 95.62 | 7.52 | 0.6936 | 1.52 | -1.05 | -8.49 | 2.90 |
| H. Lundbeck A/S | 17.37bn | 1.92bn | 48.19bn | 5.87k | 25.05 | 3.42 | 12.28 | 2.78 | 9.66 | 9.66 | 87.38 | 70.83 | 0.6138 | 1.61 | 4.77 | 2,991,044.00 | 6.79 | 4.10 | 9.34 | 6.15 | 80.62 | 76.00 | 11.06 | 5.71 | 0.8025 | 14.63 | 0.4361 | 112.00 | -5.97 | 4.81 | -31.74 | -- | -22.11 | -- |
| Ipsen SA | 20.06bn | -408.92m | 49.72bn | 5.81k | -- | 3.78 | 56.29 | 2.48 | -0.6678 | -0.6174 | 32.35 | 21.07 | 0.7009 | 2.37 | 5.24 | 463,716.20 | -1.51 | 7.30 | -2.21 | 10.15 | 81.88 | 80.30 | -2.16 | 9.85 | 0.7797 | 47.59 | 0.3727 | 36.98 | 14.67 | 15.11 | -114.17 | -- | 27.16 | 3.30 |
| Croda International Plc | 11.46bn | 1.86bn | 57.86bn | 4.58k | 31.33 | 8.08 | 23.97 | 5.05 | 1.72 | 1.72 | 10.61 | 6.68 | 0.7244 | 3.11 | 6.12 | 300,807.90 | 11.77 | 13.60 | 14.16 | 16.50 | 37.18 | 36.74 | 16.24 | 16.55 | 0.8879 | 22.50 | 0.4202 | 80.13 | -0.6634 | 5.65 | -6.04 | 6.26 | 11.37 | 5.31 |
| Vifor Pharma AG | 13.15bn | 1.11bn | 64.77bn | 2.79k | 58.14 | 2.78 | 19.59 | 4.93 | 2.45 | 2.45 | 28.86 | 51.12 | 0.3981 | 2.42 | 3.83 | 671,868.30 | 5.80 | 5.70 | 7.24 | 8.02 | 59.43 | 44.78 | 14.58 | 12.76 | 1.96 | 21.10 | 0.1471 | 80.02 | 18.47 | -11.29 | 4.40 | -10.97 | 14.27 | 5.92 |
| Qiagen NV | 10.22bn | -205.33m | 68.95bn | 5.10k | -- | 4.10 | 55.18 | 6.75 | -0.1311 | -0.1311 | 5.97 | 9.67 | 0.2924 | 3.13 | 4.36 | 269,192.10 | -0.5876 | 1.40 | -0.7193 | 1.57 | 66.07 | 65.32 | -2.01 | 4.79 | 1.41 | 7.29 | 0.4074 | -- | 1.64 | 2.57 | -121.77 | -- | 23.16 | -- |
Data as of Jul 10 2020. Currency figures normalised to H Lundbeck A/S's reporting currency: Danish Krone DKK
6.58%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Norges Bank Investment Managementas of 31 Dec 2019 | 2.49m | 1.25% |
| Invesco Advisers, Inc.as of 31 Mar 2020 | 2.00m | 1.00% |
| The Vanguard Group, Inc.as of 31 May 2020 | 1.80m | 0.91% |
| Handelsbanken Fonder ABas of 30 Jun 2020 | 1.67m | 0.84% |
| BlackRock Fund Advisorsas of 04 Jun 2020 | 1.42m | 0.71% |
| Polar Capital LLPas of 29 May 2020 | 966.40k | 0.49% |
| Dimensional Fund Advisors LPas of 30 Jun 2020 | 870.94k | 0.44% |
| UBS Asset Management (UK) Ltd.as of 02 Jun 2020 | 639.56k | 0.32% |
| SEB Investment Management ABas of 30 Apr 2020 | 622.07k | 0.31% |
| BlackRock Advisors (UK) Ltd.as of 04 Jun 2020 | 621.72k | 0.31% |
More ▼
Data from 31 Dec 2019 - 31 Mar 2020Source: FactSet Research Systems Inc.
